Calcipotriol
Calcipotriol has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 6, 2022: “Skin chronological aging drives age-related bone loss via secretion of cystatin-A”.
None of its findings points the other way.
- 1 lab in 1 country
- 2 trials, none about aging
- Funders: Bureau of Science and Information Technology of Guangzhou Municipality | Guangzhou Municipal Science and Technology Project and 3 more
- Animals1
What did studies of Calcipotriol find?
2Studies of Calcipotriol measured 2 outcomes; the most studied are senile osteoporosis (1 study) and CSTA (1).
Senile osteoporosis
downin mice1
1 study
Senile osteoporosis
downin mice1
Calcipotriol decreases senile osteoporosis in mice.
“topical application of calcipotriol stimulates Csta production in the epidermis and alleviates osteoporosis.”
Animalstopical
Skin chronological aging drives age-related bone loss via secretion of cystatin-A
Nature aging
CSTA
upin mice1
1 study
CSTA
upin mice1
Calcipotriol increases CSTA in mice.
“topical application of calcipotriol stimulates Csta production in the epidermis and alleviates osteoporosis.”
Animalstopicalepidermis
Skin chronological aging drives age-related bone loss via secretion of cystatin-A
Nature aging
Who is developing Calcipotriol?
1 company: LEO Pharma.
- Companies
- LEO PharmaPhase 3psoriasis vulgaris
Trial sponsors
Company1 trialPhase 31,245 people
1 trial3 people